Pacira BioSciences, Inc.
PCRX Nasdaq
SEC CIK 1396814
Follow Pacira BioSciences
Weekly email: filings, results
Revenue, last quarter
$176.7M
−1.6% vs same quarter last year
Net income
$28.5M
+425.1% vs same quarter last year
EPS, diluted
$0.70
+483.3% vs same quarter last year
Operating cash flow
$50.1M
−17.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $726.4M | $7M |
| FY24 | $701M | −$99.6M |
| FY23 | $675M | $42M |
| FY22 | $666.8M | $15.9M |
| FY21 | $541.5M | $42M |
| FY20 | $429.6M | $145.5M |
| FY19 | $418.9M | −$11M |
| FY18 | $332.4M | −$471K |
| FY17 | $284.3M | −$42.6M |
| FY16 | $270.1M | −$37.9M |
| FY15 | $249M | $1.9M |
| FY14 | $197.7M | −$13.7M |
| FY13 | $85.6M | −$63.9M |
| FY12 | $39.1M | −$52.3M |
| FY11 | $15.7M | −$43.3M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 79.4% | 2.6% | 1% |
| FY24 | 75.7% | −10.5% | −14.2% |
| FY23 | 72.6% | 13% | 6.2% |
| FY22 | 70.1% | 9% | 2.4% |
| FY21 | 74.1% | 16.6% | 7.8% |
| FY20 | 72.7% | 10.8% | 33.9% |
| FY19 | 74.5% | 2.5% | −2.6% |
| FY18 | 73.9% | 4.8% | −0.1% |
| FY17 | 69.1% | −8.8% | −15% |
| FY16 | 59.2% | −11.9% | −14.1% |
| FY15 | 71.1% | 3.8% | 0.7% |
| FY14 | 60.8% | −2.6% | −6.9% |
| FY13 | 36% | −62.3% | −74.7% |
| FY12 | 17.8% | −126.1% | −133.8% |
| FY11 | −6.7% | −249.2% | −276.2% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $136.7M |
| FY24 | $178.8M |
| FY23 | $139.5M |
| FY22 | $115.2M |
| FY21 | $79.9M |
| FY20 | $39.2M |
| FY19 | $60.4M |
| FY18 | $34.4M |
| FY17 | −$1.5M |
| FY16 | $8.7M |
| FY15 | −$12.3M |
| FY14 | $3.6M |
| FY13 | −$56M |
| FY12 | −$88.4M |
| FY11 | −$37.2M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $148.3M |
| FY24 | $25M |
| FY23 | $0 |
| FY22 | $0 |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Pacira BioSciences
- Healthcare median
Show the numbers
| Year | Pacira BioSciences | Healthcare median |
|---|---|---|
| FY25 | 1% | −30.6% |
| FY24 | −14.2% | −47% |
| FY23 | 6.2% | −58% |
| FY22 | 2.4% | −80.4% |
| FY21 | 7.8% | −71.8% |
| FY20 | 33.9% | −62.2% |
| FY19 | −2.6% | −46.2% |
| FY18 | −0.1% | −49.6% |
| FY17 | −15% | −45.9% |
| FY16 | −14.1% | −36% |
| FY15 | 0.7% | −37.8% |
| FY14 | −6.9% | −35.5% |
| FY13 | −74.7% | −37.1% |
| FY12 | −133.8% | −29.1% |
| FY11 | −276.2% | −27.9% |